A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination with Atezolizumab in Participants with Advanced and/or Metastatic Solid Tumors
This study is looking at a new treatment for adults who have advanced solid tumours, which means cancer that started in an organ and may have spread to other parts of the body. The new medicine is called RO7284755. Researchers want to find out how safe it is and if it can help stop the cancer from growing or even shrink it. They will test RO7284755 on its own and also in combination with another approved cancer drug called Atezolizumab. This is an early-stage study, meaning it's one of the first times this new medicine is being given to people. The aim is to gather important information that can help doctors decide if this treatment could be useful for more patients in the future.
At a glance
What is this study about?
This research study is about finding new ways to treat advanced solid tumours. Solid tumours are cancers that form a lump, rather than being in the blood, and can occur in many parts of the body like the lung, breast, or bowel. 'Advanced' means the cancer may have grown or spread.
The study is testing a new medicine called RO7284755. Since this is an early-stage study, it's one of the first times this particular medicine will be given to people. The doctors want to carefully observe how the body reacts to the medicine, checking for any side effects and seeing if it helps to control the cancer. They will investigate RO7284755 by itself and in combination with an existing cancer drug called Atezolizumab.
The aim of this research is to see if these treatments are safe and if they could be effective in fighting cancer. The information gathered from studies like this is really important because it helps scientists and doctors understand if new medicines have the potential to become future treatments for more patients. Your participation could help advance our understanding of how to treat these types of cancers.
Key takeaways
- This study tests a new cancer medicine, RO7284755, for advanced solid tumours.
- It's an early-stage study checking safety and how well the treatment works.
- The new medicine is tested alone or with Atezolizumab.
- Open to adults aged 18 and over with advanced solid tumours.
- Your participation could help develop future cancer treatments.
Who may be eligible?
This study is looking for adults who have been diagnosed with an advanced solid tumour. A solid tumour is a cancer that forms a mass or lump, unlike blood cancers. 'Advanced' means the cancer may have spread from where it started to other parts of the body.
To join, you must be 18 years old or older. The study is open to both men and women. There will be other health checks and medical conditions that the study doctors will need to review to make sure this study is right and safe for you.
It's important to discuss your full medical history with the study team, as certain health conditions or past treatments might mean this study isn't suitable for you. They will explain everything clearly.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with an advanced solid tumour?
- Are you able to attend regular hospital visits and appointments?
- Are you generally well enough to participate in a clinical study?
What does participation involve?
If you decide to take part in this study, you will have regular visits to the hospital or clinic. These visits will involve various tests, such as blood tests, scans (like X-rays or CT scans), and physical examinations, to check your health and how the treatment is affecting your cancer. You’ll receive the study medication, RO7284755, which might be given alone or with Atezolizumab. The way you receive the medication, for example, as a tablet or through an intravenous drip, will be fully explained.
You will be closely monitored throughout the study for any side effects. The total length of your participation can vary, but generally involves a treatment period followed by a follow-up period where your health continues to be checked. Your study doctor will give you a detailed schedule of visits and treatments.
Potential risks and benefits
Locations (5)
- —UnverifiedDenmark
- —UnverifiedSpain
- —UnverifiedPoland
- —UnverifiedNetherlands
- —UnverifiedBelgium
Common questions
What is a 'solid tumour'?
A solid tumour is a type of cancer that forms a mass or lump, like in the lung, breast, or bowel, as opposed to cancers that affect the blood.
What does 'advanced' mean in this study?
'Advanced' means the cancer may have grown larger, or has spread from where it started to other parts of the body.
How is this new drug given?
The study team will explain exactly how the new medicine, RO7284755, is given. This could be by mouth, injection, or through a drip, depending on the specific study plan.
Will I receive the new drug, or will I get a 'dummy' treatment?
In this early-stage study, all participants who receive treatment will get the active study drug, RO7284755, either by itself or with Atezolizumab. There is no 'dummy' (placebo) treatment in this particular study.
What happens if I want to stop participating?
You are free to leave the study at any time, for any reason, without having to explain why. This will not affect the quality of your healthcare.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.